David A. Siegel Talaris Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TALS
# of Institutions
3Shares Held
75.7KCall Options Held
0Put Options Held
0About Talaris Therapeutics, Inc.
- Ticker TALS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,995,900
- Market Cap $109M
- Description
- Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...